• GlucoTrack posted a net loss of USD 4.33 million for quarter ended March 31, 2026, narrowing from USD 6.83 million a year earlier.
• Research and development expense rose 13.95% to USD 2.13 million, driven by higher product design, development and manufacturing work plus pre-clinical animal studies.
• General and administrative costs climbed 27.29% to USD 2.07 million on higher professional fees and personnel costs, while other expense dropped to USD 131,000.
• Cash and cash equivalents fell to USD 3.93 million as of March 31, 2026, from USD 7.38 million at Dec. 31, 2025; management flagged substantial doubt about going concern based on current operating plans.
• Submitted an IDE application to FDA after quarter-end to start a U.S. clinical study for implantable continuous blood glucose monitor, following closure of long-term feasibility study in Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023205), on May 14, 2026, and is solely responsible for the information contained therein.